Bruker 8-K

Summary

Segment reporting reorganization and historical recast, effective 7/1/2026. Bruker combined divisions from its former BioSpin and CALID segments into BSI Biosystems (BIOS) and created BSI Microbiology and Infection Diagnostics (BMID); the change is intended to streamline decision-making and sharpen accountability and customer focus. The recast changes how historical segment results are presented, not Bruker’s consolidated results, financial position or cash flows, and is not a restatement.

Key Figures

• BIOS, combining divisions from former BioSpin and CALID and including the new Mimetas division following a majority-interest acquisition in Q3 2026: FY2025 external revenue was $1.58B and operating income $169M; H1 2026 revenue was $758M vs $726M in H1 2025, with an operating loss of $18.4M vs income of $58.7M.
• BMID, comprising Microbiology, Molecular Diagnostics and Biomedical Systems: FY2025 external revenue was $509M and operating income $88.8M; H1 2026 revenue was $262M vs $243M in H1 2025, and operating income was $58.8M vs $49.4M.
• BSI NANO, unchanged in the reorganization: FY2025 external revenue was $1.08B and operating loss $71.8M; H1 2026 revenue was $507M vs $509M in H1 2025, and operating loss was $42.7M vs $20.4M.
• BEST, unchanged in the reorganization: FY2025 external revenue was $263M and operating income $19.4M; H1 2026 revenue was $135M vs $121M in H1 2025, and operating income was $15.0M vs $14.1M.